Global Graft Versus Host Disease (GvHD) Treatment Market 2023
Market Overview

The GvHD treatment market was valued at USD 678.1 million in 2022 and is projected to reach USD 1,039 million by 2029, with a CAGR of 6.0%. GvHD occurs when the donor’s T-cells attack the recipient’s healthy tissues after transplant procedures. The United States had the highest number of HSCTs, followed by China and Germany. The demand for allo-HSCT is growing due to increased incidence of leukemia and lymphoma, improved transplant success rates, and an aging population.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global GvHD treatment market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Market Segmentation

The market is segmented based on various factors, including drug class, treatment type, gender, and geography.
Drug class: calcineurin inhibitors, corticosteroids, kinase inhibitors, TNF-alpha inhibitors, others
Treatment type: acute GvHD, chronic GvHD, GvHD prophylaxis
Gender: females, males

Segmentation by Geography
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan

Corticosteroid drugs are projected to hold a significant share in the global GvHD treatment market, with kinase inhibitors expected to be the fastest-growing segment. Corticosteroids are commonly recommended as front-line therapy due to their safety and efficacy compared to alternative drugs. Acute GvHD is anticipated to contribute significantly to the market, affecting 30% to 50% of individuals undergoing stem cell transplantation. Males currently dominate the market, but females are projected to be the fastest-growing segment. The United States is currently dominant, but China is expected to exhibit faster growth. Factors driving the US market include increasing incidence of GvHD, presence of key players, and improved healthcare accessibility.

Competitive Landscape

Key players in the GvHD treatment market include AltruBio, Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd., Elsalys Biotech SAS, Equillium, Inc., F. Hoffmann-La Roche AG, Genentech, Inc., GSK plc, Incyte Corporation, Janssen Global Services, LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co., Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics, Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V., among others.

Scope of the Report

To analyze and forecast the market size of the global GvHD treatment market.
To classify and forecast the global GvHD treatment market based on drug class, treatment type, gender, geography.
To identify drivers and challenges for the global GvHD treatment market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global GvHD treatment market.
To identify and analyze the profile of leading players operating in the global GvHD treatment market.

Why Choose This Report

Gain a reliable outlook of the global GvHD treatment market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Global Graft Versus Host Disease (GvHD) Treatment Market 2023

Interested in this report? Get your FREE sample now!
Global Graft Versus Host Disease (GvHD) Treatment Market 2023 - Report Scope
REPORT ATTRIBUTE

DETAILS

Market Size (2022)

USD 678.1 Million

Base Year

2022

Forecast Year

2023-2029

CAGR (2023-2029)

6.04%

Pages

93

Segments By

Drug Class, Treatment Type, Gender, Geography

Regions Covered

Global

Key Players

AltruBio Inc., ASC Therapeutics Inc., Bristol-Myers Squibb Company, Chia Tai-Tianqing Pharmaceutical Holdings Co. Ltd., Elsalys Biotech SAS, Equillium Inc., F. Hoffmann-La Roche AG, Genentech Inc., GSK plc, Incyte Corporation, Janssen Global Services LLC, Jazz Pharmaceuticals plc, JCR Pharmaceuticals Co. Ltd., Kadmon Corporation (Sanofi S.A.), MaaT Pharma SA, Mallinckrodt PLC, medac GmbH, Merck Corporation, Mesoblast Limited, MiNK Therapeutics Inc., Neovii Pharmaceuticals AG, Novartis AG, Pharmacyclics LLC, Pluri Inc., REGiMMUNE Corporation, Sun Pharmaceutical Industries Ltd., Syndax Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Xenikos B.V.

Related Reports

$2,950.00

Want to customize this report?
The present report possesses the flexibility to be tailored to your specific needs. Our team of analysts and industry experts will collaborate directly with you to gain a comprehensive understanding of your requirements.
Scroll to Top

Download Free Sample - Global Graft Versus Host Disease (GvHD) Treatment Market 2023

Please fill out our form and we will get back to you.